Last year, this biotech firm had a $50 stock and $3 billion market cap. Today, it has a stock trading below $16 and a market cap of just $870 million. But it also has a novel treatment for multiple sclerosis that has shown signs of improving the condition of MS patients, not just slowing the progression of the disease like most treatments – and that could make this out-of-favor stock worth a second look. CLICK HERE.
